Cangrelor Injection for Periprocedural Myocardial Infarction

Overview:

Periprocedural myocardial infarction (MI) refers to a heart attack that occurs around the time of a procedure, like stent placement. Cangrelor injection helps to reduce the risk of such events by preventing platelets from sticking together and forming clots in the arteries. It is an important preventive measure in high-risk patients undergoing invasive cardiac procedures. The United States Food and Drug Administration (USFDA) approved a Cangrelor injection for periprocedural myocardial infarction (MI) on June 22, 2015.

Drug Group:

Cangrelor, an intravenous, direct-acting, reversible P2Y12 (predominant receptor involved in the ADP-stimulated activation of the glycoprotein IIb/IIIa receptor) inhibitor, is utilized for patients undergoing percutaneous coronary intervention (PCI) who have not received oral P2Y12 inhibitors yet. One benefit of Cangrelor compared to oral P2Y12 inhibitors like Prasugrel, Ticagrelor, and Clopidogrel is its active form, eliminating the need for metabolic conversion, thus ensuring swift onset and offset of action. Cangrelor is an antiplatelet medication that prevents blood clots in people with certain heart or blood vessel conditions. It is typically administered intravenously in the hospital setting, especially during procedures like percutaneous coronary intervention (PCI) or stenting. It helps reduce the risk of periprocedural myocardial infarction (MI) or heart attack during these procedures.

Dosages:

The lyophilized powder of Cangrelor injection, 50 mg (milligrams), is provided in a single-use 10 mL glass vial for reconstitution.

For Patients:

What Is Periprocedural Myocardial Infarction?

The term "periprocedural myocardial infarction" (MI) describes a heart attack that happens during or right after a medical procedure, including coronary angioplasty or cardiac surgery. It may result from issues during the surgery, such as damage to the coronary arteries or obstruction of blood supply to the heart muscle.

What Is the Management of Periprocedural Myocardial Infarction?

• Quick Recognition: Rapid detection of periprocedural MI through alterations of clinical signs in the electrocardiogram (ECG) and cardiac biomarkers.

• Medical Therapy: The right medical therapy, such as beta-blockers, statins, antiplatelet medicines, and anticoagulants, should be started to stabilize the patient and prevent additional heart damage.

• Revascularization: Depending on the degree and severity of coronary artery disease, determining if immediate revascularization is necessary may involve percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).

• Monitoring and Supportive Treatment: The patient's cardiac function, electrolyte balance, and hemodynamic condition are continuously monitored, and appropriate supportive treatment is provided as necessary.

• Secondary Prevention: Reducing the risk of recurring occurrences using secondary preventive strategies such as long-term medication adherence, cardiac rehabilitation, and lifestyle adjustments.

• Risk Factor Modification: To improve long-term results, aggressively address modifiable risk factors such as diabetes, high blood pressure, high cholesterol, and smoking.

• Follow-up: Consistent follow-up visits with a cardiologist to evaluate the patient's condition, make medication adjustments, and offer continuing assistance and education.

How Does Cangrelor Injection Work?

Cangrelor inhibits platelet activation and aggregation, thus preventing the formation of blood clots. It is a reversible antagonist of the P2Y12 adenosine diphosphate (ADP) receptor subtype on platelets. By blocking these receptors, cangrelor prevents platelets from becoming activated and sticking together, which reduces the risk of thrombotic events such as myocardial infarction or stent thrombosis. Its rapid onset of action and short duration of effect make it particularly useful during PCI procedures where immediate antiplatelet activity is necessary.

What Are the Benefits of Using Cangrelor Injection for Periprocedural Myocardial Infarction?

• Quick Action: An injection of Cangrelor immediately inhibits platelets, which is essential for avoiding periprocedural myocardial infarction (MI) during angioplasty procedures.

• Short Duration of Action: When the infusion is discontinued, its effects quickly wear off, lowering the possibility of bleeding problems after the treatment.

• Strong Antiplatelet Action: Cangrelor reduces the risk of thrombotic events both during and after the surgery by efficiently blocking platelet aggregation.

• Reversible Action: Cangrelor's effects can be quickly reversed if necessary, such as in an emergency or if bleeding occurs, in contrast to several other antiplatelet medicines.

• Decreased Risk of Stent Thrombosis: Cangrelor inhibits platelet aggregation, helping lessen the possibility of stent thrombosis, a dangerous side effect of cardiac procedures.

What Must the Patient Inform the Doctor Before Taking Cangrelor Injection?

Before administering a Cangrelor injection, patients should disclose to their doctor any allergies they may have, particularly to other antiplatelet drugs. They should also disclose their medical history, including any bleeding problems, recent surgeries, or other diseases that would impair their capacity to take the medicine properly. Patients should also inform their doctor about any other prescription drugs, dietary supplements, or herbal remedies, as they could interact with Cangrelor.

What Are the Side Effects of Using Cangrelor Injection?

• Bleeding (including nosebleeds and gastrointestinal bleeding).

• Bruising or discoloration at the injection site.

• Shortness of breath.

• Headache.

• Nausea or vomiting.

• Dizziness or lightheadedness.

• Low blood pressure.

• Fever or chills.

• Allergic reactions (rash, itching, swelling).

• Irregular heartbeat or palpitations.

For Doctors:

Description:

Cangrelor injection, a direct-acting inhibitor of the P2Y12 platelet receptor, functions by blocking ADP-induced platelet activation and aggregation. Its chemical structure closely resembles adenosine triphosphate (ATP). Cangrelor injection's chemical name is the tetrasodium salt of N6-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)-5’-adenylic acid, mon anhydride with (dichloromethylene) bisphosphonic acid. It has an empirical formula of C17H21N5Cl2F3Na4O12P3S2 and an 864.3 g/mol molecular weight.

Therapeutic Uses of Cangrelor Injection:

• Cangrelor injection is an antiplatelet medication to prevent blood clots in patients undergoing percutaneous coronary intervention (PCI), such as angioplasty or stent placement.

• It is particularly beneficial in patients who require rapid and potent platelet inhibition during these procedures.

• Cangrelor can help reduce the risk of thrombotic events, such as myocardial infarction or stent thrombosis, in high-risk patients.

• It may also be utilized in patients with acute coronary syndrome (ACS) undergoing PCI to prevent further clot formation and complications.

Dosage and Administration:

The recommended dosage of Cangrelor injection involves administering a 30 mcg/kg (micrograms per kilogram) IV bolus, followed by a 4 mcg/kg/min (micrograms per kilogram per minute) IV infusion. Start the bolus infusion before PCI. The maintenance infusion should typically continue for at least two hours or the duration of PCI, whichever is longer. To maintain platelet inhibition after stopping the Cangrelor injection infusion, administer an oral P2Y12 platelet inhibitor as follows:

• Ticagrelor: 180 mg during Cangrelor injection infusion or immediately after discontinuation.

• Prasugrel: 60 mg right after stopping the Cangrelor injection.

• Clopidogrel: 600 mg(milligrams) immediately after discontinuing Cangrelor injection.

Indications:

Cangrelor injection is recommended as an addition to percutaneous coronary intervention (PCI) to lower the chances of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not received a P2Y12 platelet inhibitor and are not receiving a glycoprotein IIb/IIIa inhibitor.

Contraindications:

Cangrelor injection should not be used in patients experiencing significant active bleeding or known hypersensitivity reactions, such as anaphylaxis, to Cangrelor injection or any of its components.

• Hypersensitivity: The injection should not be administered to anyone with a history of recognized hypersensitivity or allergy to cangrelor or its ingredients.

• Active Bleeding: Cangrelor injections should not be administered to patients who are bleeding actively, such as those who have internal bleeding or cerebral hemorrhage, as this could exacerbate their condition.

• Severe Liver illness: Patients with severe liver illness should use Cangrelor with caution or not at all, as it may change their metabolism and cause problems.

• Severe Renal Impairment: Due to reduced medication clearance, patients with severe renal impairment may need to avoid or change their Cangrelor dosage.

• History of Stroke: Patients having a history of stroke may be at higher risk, especially if it occurred recently or if there are additional risk factors.

• Coagulation Disorders: Individuals should use Cangrelor with caution or avoid it completely if they have a known coagulation disease or are at a high risk of bleeding from other medical conditions.

Warnings and Precautions:

Medications like Cangrelor injection, which hinder platelet P2Y12 function, heighten the likelihood of bleeding. Regardless of severity, Bleeding incidents occurred more frequently with Cangrelor injection than Clopidogrel. The bleeding risks associated with Cangrelor injection remained consistent across various clinically significant subgroups. After discontinuing the Cangrelor injection, there is no lingering antiplatelet effect within an hour.

What Are the Adverse Reactions of Cangrelor Injection?

• Cough.

• Difficulty with swallowing.

• Fast heartbeat.

• Hives.

• Itching or rash.

• Large, hive-like swelling on the face, eyelids, lips, and tongue.

What Are the Pharmacological Aspects of Cangrelor Injection?

1. Mechanism of Action: Cangrelor, functioning as a direct inhibitor of the P2Y12 platelet receptor, obstructs ADP-induced activation and aggregation of platelets. It selectively and reversibly binds to the P2Y12 receptor, effectively halting further signaling and activation of platelets.

2. Pharmacodynamics: Cangrelor, when given as a 30 mcg/kg (micrograms per kilogram per minute) IV bolus followed by a 4 mcg/kg/min (micrograms per kilogram per minute) IV infusion, rapidly inhibits platelet activation and aggregation within two minutes. The antiplatelet effect persists throughout the infusion period but diminishes quickly after its discontinuation, with platelet function returning to normal within one hour.

3. Pharmacokinetics:

• When given intravenously, Cangrelor injection exhibits linear pharmacokinetics in healthy individuals and patients. It is rapidly distributed and metabolized, reaching its maximum concentration (Cmax) within two minutes after an intravenous bolus followed by infusion in a study involving healthy volunteers, administration of Cangrelor injection at a dose of 30 mcg/kg (micrograms per kilogram)bolus plus four mcg/kg/min (micrograms per kilogram per minute) resulted in a volume of distribution of 3.9 Liters. The plasma protein binding of Cangrelor injection is approximately 97 to 98 percent.

• Cangrelor injection undergoes rapid deactivation in the bloodstream through dephosphorylation to its primary metabolite, a nucleoside with minimal antiplatelet activity. Its metabolism is not reliant on liver function and does not disrupt the metabolism of other drugs processed by hepatic enzymes.

• After intravenous administration, approximately 58 percent of the administered Cangrelor injection is excreted in urine, with the remaining 35 percent eliminated in feces, likely via biliary excretion. Cangrelor injection typically has an elimination half-life of three to six minutes. Cangrelor injection's pharmacokinetics remain consistent regardless of sex, age, renal function, or hepatic function, necessitating no dose adjustments based on these factors. While weight influences drug clearance, its impact on drug exposure is managed through weight-based dosing.

Drug Interactions:

• Abrocitinib.

• Acalabrutinib.

• Caplacizumab.

• Clopidogrel.

• Fish oil triglycerides.

• Ibrutinib.

• Prasugrel.

• Selumetinib.

• Warfarin.

Use in Specific Populations:

• Pregnancy: There is insufficient data on the use of Cangrelor in pregnant women to assess potential risks of birth defects, miscarriage, or adverse outcomes for either the mother or fetus. However, untreated myocardial infarction poses significant risks to both. Animal studies involving pregnant rats and rabbits receiving Cangrelor at doses approximately double the recommended human dose during organogenesis did not show fetal malformations. The baseline risk of major birth defects and miscarriage in the general population is unknown. Statistically, it ranges from two to four percent and 15 to 20 percent in recognized pregnancies in the U.S.

• Lactating Mothers: There is a lack of data regarding the presence of Cangrelor in human or animal milk, its impact on breastfed infants, or milk production. However, due to its short half-life, Cangrelor exposure in breastfed infants is anticipated to be minimal.

• Pediatrics: Safety and efficacy in pediatric patients have not been confirmed.

• Geriatrics: In the study, 18 percent of patients were 75 years or older, and there were no notable differences in safety or efficacy compared to younger patients.

• Renal Impairment: Dosage adjustment is unnecessary for patients with mild, moderate, or severe renal impairment.

Clinical Studies:

The trial aimed to determine if rapid platelet inhibition using Cangrelor during PCI could decrease periprocedural thrombotic events compared to the slower-acting Clopidogrel. It was a randomized, double-blind study involving patients with coronary artery disease undergoing PCI. The primary outcome measured the occurrence of a composite endpoint within 48 hours after randomization. Cangrelor injection, administered as a bolus followed by infusion, significantly reduced the occurrence of primary composite endpoint events compared to Clopidogrel. This reduction mainly involved post-procedural MIs detected solely by CK-MB (a blood test that looks for a specific enzyme) elevation, but Cangrelor injection did not reduce mortality risk.

Due to the diverse conditions under which clinical trials are conducted, the rates of adverse reactions observed in one drug's trials cannot be directly compared to those of another. Furthermore, these rates may not necessarily reflect real-world practice. Cangrelor injection's safety profile was assessed in 13,301 individuals across controlled trials, with 5,529 participants included.